Novo Nordisk appoints new CEO Maziar Doustdar
July 29 (UPI) -- Novo Nordisk announced Tuesday that Mike Doustdar has been appointed as the company's new CEO.
Doustdar steps into the role succeeding Lars Fruergaard Jorgensen, effective Aug. 7, 2025, which will also serve as Joregensens last day.
"Mike is an exceptional leader and has the unanimous support of the board. We are confident that he is the best person to lead Novo Nordisk through its next growth phase. Mike has consistently demonstrated the ability to drive growth through strong commercial execution and building high-performing teams," Novo Nordisk Chair Helge Lund said in a press release. "This is an important moment for Novo Nordisk. The market is developing rapidly, and the company needs to address recent market challenges with speed and ambition. I believe Novo Nordisk will build on its strengths as a global leader in obesity and diabetes, and Mike has a clear vision of how to unlock the full potential of the opportunities ahead."
"It's an enormous privilege to lead this company at a time of tremendous opportunity and change. I come to this role with a sense of urgency, a laser focus on high performance, and a fierce determination for Novo Nordisk to aim higher than it's ever done, and to deliver to many more patients the innovation they need," said Doutsdar.
Novo Nordisk is also announcing its merging the company's Research & Early Development with its Development area into a consolidated R&D unit.
The company has also recently ended its partnership with Hims & Hers over its sale and promotion of a cheaper version of Wegovy, a weight loss drug last month.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Politico
an hour ago
- Politico
How California missed its chance to protect solar funding from Trump
With no official EPA announcement on the Solar for All funding out yet, the CPUC is taking a diplomatic stance. 'The CPUC is actively implementing Solar for All under a stakeholder-driven, EPA-approved workplan,' said agency spokesperson Terrie Prosper. California has about 217 megawatts of capacity of community solar installed or in the pipeline — far less than leading states like Florida (3,873 MW) or New York (2,110 MW). And while other states also haven't spent all their Solar for All awards, some are much further along than California. Illinois, for example, has spent $11 million of its $156 million, according to U.S. spending data analyzed by the firm Atlas Public Policy. California has spent $100,641, according to Atlas' figures. 'California, rather than being a leader in this clean energy aspect, has been a laggard,' said Derek Chernow, western regional director of the Coalition for Community Solar Access, a group of solar developers. California officials have defended the state against other federal provocations on renewable energy, including by suing over lost EV charging funding, proposing a plan to replace lost EV tax credits with state dollars, and weighing fast-tracked permits for renewable energy projects cut off from federal incentives. It's unclear whether the state wants to go to bat for community solar. Asked whether California would sue once the Trump administration terminates the grants, a spokesperson for Attorney General Rob Bonta said the office does not comment on legal strategy. But the episode illustrates how California's window of opportunity is narrowing to get renewable energy projects reliant on federal funding off the ground before the Trump administration quashes them. A bill sponsored by the community solar industry that would have had CPUC redo the tariff and speed up the program failed in the Assembly Appropriations Committee in May. Assemblymember Chris Ward, the author of AB 1260, said he hopes to bring it back next year. 'I've always said that a successful program shouldn't rely on one-time federal funding to survive,' Ward said in a statement. Like this content? Consider signing up for POLITICO's California Climate newsletter.
Politico
an hour ago
- Politico
The California solar initiative that never was
With help from Alex Nieves THROWING SHADE: The Trump administration wants to cancel community solar. In California, the technology never even got off the ground. Almost none of the $250 million that California received from the Inflation Reduction Act's Solar for All program, which the Trump administration is making plans to terminate as soon as this week, has made it out the door yet. Solar companies fear they're on the cusp of losing their best shot at setting up a thriving program in the state for so-called community solar. The dream is to give renters and electricity customers who can't afford to put panels on their rooftops the chance to draw from nearby mid-sized solar installations. But it hasn't gone far in California. 'It's really tragic,' said Joe Henri, senior vice president of policy at community solar developer Dimension Energy. 'California's very elaborate plans are really in jeopardy.' Advocates like Henri aren't just blaming the feds, though. Rather, they're placing a big share of the responsibility at the feet of the California Public Utilities Commission. The EPA announced in April 2024 that it was giving the state a $250 million award. To date, the CPUC, which is responsible for the grant, has distributed next to nothing. The agency set up a tariff structure for community solar programs in May 2024, and said it would use the Solar for All funding to augment the payments, which advocates said would be too stingy to incentivize projects. But that wasn't the end. In that decision, the agency asked utilities and community choice aggregators to file a slew of additional advisory paperwork. The back and forth between the CPUC and interest groups continued on from there. In April 2025, a year after the original EPA award announcement, Administrative Law Judge Valerie Kao put out a notice asking interest groups for more feedback, including how to prudently spend the Solar for All funding before its use-it-or-lose-it deadline of April 2029. State agencies remain in an 'administrative and planning phase,' according to the CPUC website. 'The PUC's slow-walking of this process has likely squandered $250 million in federal support,' said Matthew Freedman, a staff attorney with The Utility Reform Network. 'As of today, we have no program, no development, federal tax credits that are about to sunset, and now an announcement that Solar for All funding is going to be pulled by the Trump administration.' With no official EPA announcement on the Solar for All funding out yet, the CPUC is taking a diplomatic stance. 'The CPUC is actively implementing Solar for All under a stakeholder-driven, EPA-approved workplan,' said agency spokesperson Terrie Prosper. California has about 217 MW of capacity of community solar installed or in the pipeline — far less than leading states like Florida (3,873 MW) or New York (2,110 MW). And while other states also haven't spent all their Solar for All awards, some are much further along than California. Illinois, for example, has spent $11 million of its $156 million, according to U.S. spending data analyzed by the firm Atlas Public Policy. California has spent $100,641, according to Atlas' figures. 'California, rather than being a leader in this clean energy aspect, has been a laggard,' said Derek Chernow, western regional director of the Coalition for Community Solar Access, a group of solar developers. California officials have defended the state against other federal provocations on renewable energy, including by suing over lost EV charging funding, proposing a plan to replace lost EV tax credits with state dollars, and weighing fast-tracked permits for renewable energy projects cut off from federal incentives. It's unclear whether the state wants to go to bat for community solar. Asked whether California would sue once the Trump administration terminates the grants, a spokesperson for Attorney General Rob Bonta said the office does not comment on legal strategy. But the episode illustrates how California's window of opportunity is narrowing to get renewable energy projects reliant on federal funding off the ground before the Trump administration quashes them. A bill sponsored by the community solar industry that would have had CPUC redo the tariff and speed up the program failed in the Assembly Appropriations Committee in May. Assemblymember Chris Ward, the author of AB 1260, said he hopes to bring it back next year. 'I've always said that a successful program shouldn't rely on one-time federal funding to survive,' Ward said in a statement. — NB, CvK Did someone forward you this newsletter? Sign up here! THE DELTA SHADOW: No, Gov. Gavin Newsom hasn't forgotten about his Delta tunnel request. On Wednesday, he reiterated his May proposal to fast-track a controversial tunnel routing more water to farms and cities, making sure the idea stays in the mix as lawmakers gear up to return to Sacramento to consider other big-ticket demands on cap-and-trade, refineries and electric utilities. To sweeten the deal, he paired the revived demand with a list of commitments to incorporate feedback from Delta communities in the tunnel's permitting and construction, including the creation of an ombudsman office and $200 million in community benefits. Delta-region lawmakers who successfully rejected Newsom's bid to tie the proposal to the budget in June are raring for another fight. Sen. Jerry McNerney and Assemblymember Lori Wilson quickly put out a statement saying 'no amount of money can compensate' for the tunnel's construction impacts on communities and urging instead to fortify the region's levees and invest in water recycling and groundwater storage. But compared to when the Delta-region lawmakers successfully beat back a streamlining proposal in 2023, they're facing a more eager coalition on the other side: A bipartisan group of state lawmakers, including Democrats from the Los Angeles region, which would get the water from the tunnel, and construction unions and business and water groups have already come out in support. — CvK ELECTRIC SAVINGS: Single-family homes stand to save the most on electrification upgrades in Los Angeles, according to a new UCLA report published Wednesday. The analysis uses a modeling tool the UCLA researchers developed for the Los Angeles Department of Water and Power as part of its effort to rid its grid of carbon emissions by 2035. It determined annual savings of $145 to $1,074 in 2025 for single-family households that electrified their heating and air conditioning, and savings of $70 to $303 for units in multifamily buildings. The only scenario that cost more than it saved: low-efficiency heat pumps for multifamily buildings. The report comes out, the researchers pointed out, as the Los Angeles city council considers repealing its requirement that buildings be all-electric in light of a court striking down the city of Berkeley's gas ban. — CvK NO TAKEBACKS: A federal judge isn't buying the Trump administration's argument that it didn't really cancel a FEMA grant program, despite announcing that it had pulled the plug. Judge Richard Stearns, of the United States District Court for the District of Massachusetts, ordered FEMA to hold on to $4.1 billion in funds for the Building Resilient Infrastructure and Communities program — which funds local disaster-protection projects — while he determines whether the cancellation was legal, Thomas Frank reports for POLITICO's E&E News. California has historically been the biggest grant recipient through the program, which launched in 2020. The state had received nearly a quarter of all BRIC funding — $930 million — through 2023, despite representing roughly 12 percent of the national population. Attorney General Rob Bonta joined 19 other AGs in a lawsuit last month challenging the program cancellation, noting that California could receive more than $1 billion in new grants. — AN SETTING THE AGENDA: On Wednesday, Aug. 27, POLITICO is hosting its inaugural California policy summit: The California Agenda. Come see the Golden State's most prominent political figures — including Sen. Alex Padilla and gubernatorial candidates Katie Porter and Xavier Becerra — share the stage with influential voices in tech, energy, housing and other areas at the forefront of the state's most critical policy debates. The live and streamed event is free, but advance registration is required. Stay tuned for more on speakers and discussion topics, and request an invite here. DOE TO PG&E: Pacific Gas & Electric Company has hired Dwayne Bolton, a former Trump administration staffer during the president's first term, to lobby on federal funding issues, according to a disclosure filing. Bolton, who joined Washington, D.C.-based government relations firm Mountain View Partners in January, began lobbying for PG&E in June at the height of negotiations over the phaseout of clean energy tax credits in Republicans' megabill, POLITICO's Caitlin Oprysko reports. He previously served as a congressional liaison in President Donald Trump's Department of Energy and worked in the department's Office of Economic Impact and Diversity and Office of Environmental Management. — The National Weather Service has received permission to fill hundreds of roles previously cut by DOGE. — Global insured losses from natural disasters reached $80 billion during the first half of the year, and half of that is connected to the Los Angeles fires. — Scientists say they have more proof that California's longer wildfire season is linked to climate change.
Yahoo
4 hours ago
- Yahoo
Is Novo Nordisk Stock a Buy, Sell, or Hold Before Q2 Earnings?
Danish pharmaceutical giant Novo Nordisk A/S (NVO) is facing serious headwinds. After enjoying a strong run fueled by demand for its obesity treatments, the obesity drug pioneer is now under pressure from rising competition, particularly from Eli Lilly's (LLY) weight-loss drugs, as well as trial setbacks for its next-generation therapies. In fact, things took a sharp turn on July 29, when the company cut its full-year sales growth guidance for the second time in just three months and named a new CEO. The market response was swift and brutal, with NVO shares plunging over 21% in a single day. Now, with second-quarter earnings just around the corner on Aug. 6, does Novo Nordisk's recent plunge present a golden buying opportunity, or is it a clear signal to keep your distance? More News from Barchart Dear Nvidia Stock Fans, Mark Your Calendars for August 27 Options Traders Expected Palantir Stock's Tamest Earnings Reaction in a Year. Did They Get It Right? Tesla Gains on Elon Musk's New Pay Package. Is TSLA Stock a Buy? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! About Novo Nordisk Stock Best known for its blockbuster weight-loss drugs Ozempic and Wegovy, Novo Nordisk is a global healthcare leader with a long-standing focus on chronic disease. Founded in 1923 and headquartered in Denmark, the company has built a strong foundation in diabetes care while expanding its reach into obesity and other severe health conditions. The company commands a market capitalization of about $217.9 billion. While Novo Nordisk has been a trailblazer in the obesity drug market, its stock has hit a rough patch. Softer demand for its blockbuster drugs, combined with intensifying competition in the weight-loss space, has taken a toll on investor sentiment. The stock has tumbled a staggering 66% from its 52-week high of $139.74 reached in August 2024, and it's currently down 44.7% year-to-date (YTD). In stark contrast, the broader S&P 500 Index ($SPX) has managed to notch a gain of approximately 7.1% over the same period, while its rival Eli Lilly has seen only a marginal drop so far this year, highlighting just how far Novo has fallen out of favor with the market. Given its underwhelming price action, Novo Nordisk stock is starting to look like a value play. Currently trading at just 12.5 times forward earnings, it's priced well below the sector median of 16.87x, and dramatically lower than its own five-year average of 30.92x. Novo Nordisk's Q1 Earnings Snapshot In early May, Novo Nordisk posted a solid first-quarter earnings report for fiscal 2025, but the shine was dulled by a cautious outlook. Total revenue climbed 19% year-over-year (YOY) to 78.1 billion Danish kroner, powered by a massive 85% surge in Wegovy sales, which hit 17.4 billion Danish kroner. Ozempic also continued to perform, with sales rising 18% to 32.7 billion Danish kroner. Profits also impressed, with net profit climbing 14% to 29 billion Danish kroner, while operating profit increased 22% to 38.8 billion Danish kroner. But despite these promising numbers, Novo trimmed its full-year sales growth and operating profit growth guidance, citing 'lower-than-planned penetration of branded GLP-1 treatments in the US.' The company pointed to the growing presence of U.S. compounding pharmacies, which have been legally producing copycat versions of Wegovy and Ozempic under an FDA-approved exemption for addressing drug shortages. That growing parallel market has begun to chip away at Novo's momentum. On a more promising note, the company completed its REDEFINE 2 trial during the quarter, with its next-generation drug CagriSema delivering an impressive 15.7% weight loss in patients with obesity or overweight conditions and type 2 diabetes. Novo plans to file for its first regulatory approval in early 2026, potentially marking the next significant chapter in its obesity pipeline. Novo Nordisk Slashes Guidance Again and Names New CEO On July 29, Novo Nordisk held a conference call that left investors rattled, as it unveiled major leadership changes and another sharp downgrade to its 2025 financial outlook. The company slashed its full-year sales growth guidance to 8%-14%, down from the previously expected 13%-21%. Operating profit growth was also revised lower, now projected at 10%-16% compared to May's forecast of 16%-24%. The revised outlook sent a strong signal that Novo is bracing for a more challenging year ahead. A big part of the pressure comes from its obesity blockbuster, Wegovy. In its update, Novo pointed to several headwinds weighing on U.S. sales, including the continued rise of compounded GLP-1 knockoffs, slower-than-expected market expansion, and increasing competition. These challenges have clouded the outlook for one of Novo's key growth drivers, sparking concerns about whether the company can maintain its dominance in the rapidly growing weight-loss market. Adding to the uncertainty, Novo also announced a leadership shake-up. Maziar Mike Doustdar, the current EVP of international operations, will take over as CEO on Aug. 7, succeeding Lars Fruergaard Jørgensen, whose surprise resignation was announced in May. The transition comes at a pivotal moment, with the company under pressure to protect market share and reignite growth amid shifting dynamics in the obesity drug landscape. What Do Analysts Think About Novo Nordisk Stock? Despite all the swirling uncertainty, there's still a hint of optimism in the air. With Novo Nordisk set to unveil its Q2 earnings on Aug. 6 and a new CEO stepping in shortly after, Wall Street hasn't lost faith, with analysts leaning cautiously bullish, giving the stock a consensus rating of 'Moderate Buy' overall. Of the 19 analysts offering recommendations, seven advise a 'Strong Buy,' nine suggest a 'Hold,' one advocates a 'Moderate Sell,' and the remaining two maintain a 'Strong Sell.' NVO's average analyst price target of $71.75 suggests 47% potential upside from current levels. However, the Street-high target of $112 implies that shares can rally as much as 129.5% from current price levels. On the date of publication, Anushka Mukherji did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
